USPTO Grants Patent for Terpenoids in Fibrotic Disease Treatment

The United States Patent and Trademark Office (USPTO) has granted patent US12582689B2, titled 'Use of terpenoids in the treatment or prevention of fibrotic diseases,' to ARJIL BIOTECH HOLDING COMPANY LIMITED. The patent, which has an effective grant date of March 24, 2026, covers a method for preventing or treating fibrotic conditions by administering a composition containing triterpenes extracted from Antrodia-camphorate or Anisomeles indica.

This patent grant signifies new intellectual property protection for a specific therapeutic approach. While not a regulatory rule imposing obligations on other entities, it is a key development for companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in fibrotic disease research and treatment. Compliance officers should note this as a relevant IP development for competitive intelligence and potential licensing considerations.